Sun Pharma paid $11.75 billion, or $14 a share in cash, to buy Organon in a deal that positions the India-based generics maker among the world’s biosimilar heavyweights. The deal is expected to close early 2027.
Organon brings 70-plus products and six manufacturing sites across the EU and emerging markets. Post-close, Sun Pharma becomes the seventh largest biosimilar player worldwide and lands a top-three spot in women’s health globally. Managing Director Kirti Ganorkar called it a “logical next step” in building global scale, with immediate priorities around integration and business continuity.
What does the buyer actually get? Organon booked $6.2 billion in 2025 revenue, but it’s carrying $8.6 billion in debt. The New Jersey company had been examining strategic options — a signal it couldn’t sustain that load on its own. Sun Pharma’s all-cash structure is designed to create, in Ganorkar’s words, “a stronger cash generating company.”
For context on where this lands in the biosimilar race: Amneal Pharmaceuticals inked a $1.1 billion deal for Kashiv BioSciences around the same time, also targeting global biosimilar leadership. Sun Pharma’s buy is more than ten times that size.
Merck spun Organon out in 2021, handing off women’s health, biosimilars, and established-brands businesses. Sun Pharma is now buying what Merck gave up, betting the $6.2 billion revenue base is worth absorbing $8.6 billion in debt.
Diana Kowalski